2 hrs ago
Teva to Report Fourth Quarter 2013 Financial Results on February 6, 2014
Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its fourth quarter 2013 results and overall business environment.
Wed Dec 18, 2013
The Motley Fool
Amarin, Vivus, and Teva: The 3 Biggest Management Shake-Ups of 2013
We've seen some significant management changes in 2013. Microsoft made headlines for the announcement that Steve Ballmer will step down, and J.C. Penney had investors talking when it fired Ron Johnson.
Viagra, Apple, KBC Groep, Huawei: Intellectual Property
Generic Viagra will hit the market more than two years earlier than expected under a settlement reached by Teva Pharmaceutical Industries Ltd. and Pfizer Inc. , the maker of the impotence drug.
Tue Dec 17, 2013
Pfizer Settles Viagra Patent Litigation With Teva
Pfizer announced that it has settled its litigation against Teva Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use of ViagraA to treat erectile dysfunction , relating to Pfizer's patent covering the use of ViagraA to treat erectile dysfunction , which expires in April 2020 .
Pfizer will allow Teva to sell generic Viagra
Pfizer Inc on Tuesday said it would allow Teva Pharmaceutical Industries to sell generic forms of its Viagra anti-impotence treatment in the United States beginning in late 2017, in a settlement of longstanding patent litigation between the two drugmakers.
Mon Dec 16, 2013
Board changes for Teva, Roche and BMS - People on the move
We begin this week with news from generic drugmaker Teva who, having recently seen changes at the top , has announced Amir Elstein will succeed Moshe Many as vice chairman of its board of directors.
Frost: Opko's share price is extremely low
Dec. 16 --The share price of multidisciplinary biomed company Opko Health Inc. rose 1 percent on the TASE today after losing 23 percent over the past three trading days.
Results from Clinical Trials, Updated Financial Outlook, New...
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson , Teva Pharmaceutical Industries Limited , CytRx Corporation , Edwards Lifesciences Corp. and Aegerion Pharmaceuticals, Inc. .
Fri Dec 13, 2013
Teva Unveils New Pipeline Assets from the NTE Program
Nov. 19, 2013-- Developing new pipeline assets through the New Therapeutic Entities process, which was launched less than one year ago, is a major element in Teva's strategy for growth.
WEALTHMAKERS.COM Issues Research Reports on USAP, SNDK, SFY, MLNK, TEVA, MRH
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Universal ... (more)
Analyst Mean Targets Predicted Healthcare Dog Upsides
Using closing prices for Healthcare stocks as of April 26, 2013 , this report is based on analyst 1 yr target prices from stocks selected by yield from the following list of thirty: The plan in April was to use analyst estimates as a "market sentiment" gauge of upside potential.
Thu Dec 12, 2013
Teva Releases Financial Guidance Dependent on Copaxone Generic Competition
Teva Pharmaceutical Industries released a financial outlook for 2014 based on two possible scenarios concerning its top-selling multiple sc Copaxone .
Wed Dec 11, 2013
Customer Interaction Solutions
Fitch Downgrades Teva to 'BBB+'; Outlook Stable
Fitch Ratings has downgraded the ratings of Teva Pharmaceutical Industries Limited to 'BBB+' from 'A-'.
Stock Market Dailies: Teva Pharma Industries, Dynavax Technologies,...
The S&P 500 ended the day at 1,802.62, down 0.32%; the Dow Jones Industrial Average closed at 15,973.13, down 0.33%; and the NASDAQ Composite finished at 4,060.49, down 0.20%.
Five Star Equities Issues New Research Reports on ALOG, GNK, TEVA and ...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
Tue Dec 10, 2013
Teva Pharmaceutical Industries Limited Provides 2014 Financial Outlook
In an effort to enhance investor understanding of the business performance of the company, and to provide more clarity and transparency regarding its projections for 2014, given the significant uncertainty concerning possible generic competition to Copaxone.
Israel Corp chairman steps down, to be vice chair of Teva Pharm
Israeli conglomerate Israel Corp said on Tuesday its chairman Amir Elstein will step down at the end of the year after 3-1/2 years in the post.
UPDATE 1-Teva sees 2014 profit drop if Copaxone competition launched
Teva Pharmaceutical Industries , the world's biggest generic drugmaker, forecast a big drop in profit in 2014 if cheap generic competition to its blockbuster multiple sclerosis treatment Copaxone is launched.
Sun Dec 08, 2013
Teva bets on new therapeutic uses of known molecules
Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities could generate revenue of $1 billion to $1.5 billion by 2018.
Thu Dec 05, 2013
Merrill Lynch: 4 reasons to buy Teva in 2014
Dec. 05 -- Merrill Lynch has taken what it calls a "contrarian pick" for Teva Pharmaceutical Industries Ltd. , offering four reasons to buy the share in 2014.